- Home
- LLYVA vs RVMD Comparison
LLYVA vs RVMD Comparison
Compare LLYVA & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- RVMD
- Stock Information
- Founded
- LLYVA 1991
- RVMD 2014
- Country
- LLYVA United States
- RVMD United States
- Employees
- LLYVA N/A
- RVMD N/A
- Industry
- LLYVA Broadcasting
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LLYVA Industrials
- RVMD Health Care
- Exchange
- LLYVA Nasdaq
- RVMD Nasdaq
- Market Cap
- LLYVA 7.1B
- RVMD 7.5B
- IPO Year
- LLYVA N/A
- RVMD 2020
- Fundamental
- Price
- LLYVA $83.26
- RVMD $38.39
- Analyst Decision
- LLYVA
- RVMD Strong Buy
- Analyst Count
- LLYVA 0
- RVMD 12
- Target Price
- LLYVA N/A
- RVMD $69.50
- AVG Volume (30 Days)
- LLYVA 127.7K
- RVMD 1.5M
- Earning Date
- LLYVA 01-01-0001
- RVMD 08-06-2025
- Dividend Yield
- LLYVA N/A
- RVMD N/A
- EPS Growth
- LLYVA N/A
- RVMD N/A
- EPS
- LLYVA 0.27
- RVMD N/A
- Revenue
- LLYVA N/A
- RVMD N/A
- Revenue This Year
- LLYVA N/A
- RVMD N/A
- Revenue Next Year
- LLYVA $11.26
- RVMD $234.26
- P/E Ratio
- LLYVA $312.98
- RVMD N/A
- Revenue Growth
- LLYVA N/A
- RVMD N/A
- 52 Week Low
- LLYVA $34.58
- RVMD $29.17
- 52 Week High
- LLYVA $85.67
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- LLYVA 59.53
- RVMD 53.50
- Support Level
- LLYVA $77.78
- RVMD $36.20
- Resistance Level
- LLYVA $85.67
- RVMD $38.10
- Average True Range (ATR)
- LLYVA 2.58
- RVMD 1.25
- MACD
- LLYVA -0.02
- RVMD 0.05
- Stochastic Oscillator
- LLYVA 69.46
- RVMD 64.04
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.